Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Teams with Canadian Researchers on PGx Research

NEW YORK (GenomeWeb News) – Invitrogen said Monday that it will collaborate with researchers at Genome Quebec and the Montreal Heart Institute Pharmacogenomics Centre on a pharmacogenomics research project.
Specifically, Invitrogen said that the partners aim to develop novel methodologies and reagents for targeted medical resequencing.
Researchers at the Pharmacogenomics Centre are trying to identify new SNPs within around 200 specific ADME/Tox-related genes that affect drug metabolism. The collaboration with Invitrogen is meant to accelerate this effort, the partners said in a statement.
“This collaboration offers Invitrogen the opportunity to work closely with thought leaders in the field of pharmacogenomics and to better understand this emerging area of research,” said Rob Bennett, Invitrogen’s vice president of advanced sequencing applications, in a statement.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.